Spineart received a CHF 25 million (~USD $31 million) capital increase backed by investors Gimv and EGS Beteiligungen. This new funding will fuel Spineart’s next phase of profitable growth, enabling the company to advance its innovation pipeline and strengthen its global footprint.
Spineart’s profitable growth strategy is anchored in a portfolio of technologies designed to make spine surgery safer, more efficient and more effective. With a strong focus on clinical outcomes, the company is expanding across Europe and the United States with ongoing regulatory submissions to FDA for its BAGUERA C cervical disc prosthesis. Strategic partnerships and investments in digital navigation and robotics are also enhancing Spineart’s capabilities.
Spineart currently employs over 360 professionals worldwide and is projected to reach revenues of approximately €140 million (~$164 million) in 2025, reflecting five consecutive years of growth at an average annual rate of +16%. With a recently opened modern production facility in Reignier, France, the company is well-positioned to meet the rising global demand for its advanced spine surgery solutions.
“This investment represents a major milestone in Spineart’s profitable growth journey,” said Jerome Trividic, CEO of Spineart. “Over the past years, we’ve made targeted strategic investments in product innovation, robotics, regulatory expansion in Europe and the United States and manufacturing, that are now coming to fruition. With the continued support of Gimv and EGSB, we are well-positioned to scale globally, deliver innovative, differentiated technologies and reinforce our commitment to surgical excellence and improved patient outcomes.”
Spineart received a CHF 25 million (~USD $31 million) capital increase backed by investors Gimv and EGS Beteiligungen. This new funding will fuel Spineart’s next phase of profitable growth, enabling the company to advance its innovation pipeline and strengthen its global footprint.
Spineart’s profitable growth strategy is anchored in a...
Spineart received a CHF 25 million (~USD $31 million) capital increase backed by investors Gimv and EGS Beteiligungen. This new funding will fuel Spineart’s next phase of profitable growth, enabling the company to advance its innovation pipeline and strengthen its global footprint.
Spineart’s profitable growth strategy is anchored in a portfolio of technologies designed to make spine surgery safer, more efficient and more effective. With a strong focus on clinical outcomes, the company is expanding across Europe and the United States with ongoing regulatory submissions to FDA for its BAGUERA C cervical disc prosthesis. Strategic partnerships and investments in digital navigation and robotics are also enhancing Spineart’s capabilities.
Spineart currently employs over 360 professionals worldwide and is projected to reach revenues of approximately €140 million (~$164 million) in 2025, reflecting five consecutive years of growth at an average annual rate of +16%. With a recently opened modern production facility in Reignier, France, the company is well-positioned to meet the rising global demand for its advanced spine surgery solutions.
“This investment represents a major milestone in Spineart’s profitable growth journey,” said Jerome Trividic, CEO of Spineart. “Over the past years, we’ve made targeted strategic investments in product innovation, robotics, regulatory expansion in Europe and the United States and manufacturing, that are now coming to fruition. With the continued support of Gimv and EGSB, we are well-positioned to scale globally, deliver innovative, differentiated technologies and reinforce our commitment to surgical excellence and improved patient outcomes.”
Copy to clipboard 
